Yeshurun M - Search Results

1

A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors.

Robin M, Guardiola P, Devergie A, Yeshurun M, Shapiro S, Esperou H, Ribaud P, Rocha V, Gluckman E, Socié G. Robin M, et al. Among authors: yeshurun m. Leukemia. 2005 Sep;19(9):1613-20. doi: 10.1038/sj.leu.2403821. Leukemia. 2005. PMID: 15990868

2

CAR-T cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.

Shargian L, Raanani P, Yeshurun M, Gafter-Gvili A, Gurion R. Shargian L, et al. Among authors: yeshurun m. Br J Haematol. 2023 Jan;200(1):e4-e5. doi: 10.1111/bjh.18506. Epub 2022 Oct 25. Br J Haematol. 2023. PMID: 36281746 No abstract available.

3

Anti-immunoglobulin-like transcript 3 induced acute myocarditis-A case report.

Itzhaki Ben Zadok O, Shiyovich A, Hamdan A, Yeshurun M, Nardi Agmon I, Raanani P, Kornowski R, Shargian L. Itzhaki Ben Zadok O, et al. Among authors: yeshurun m. Front Cardiovasc Med. 2022 Dec 8;9:1035569. doi: 10.3389/fcvm.2022.1035569. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36568550 Free PMC article.

4

Infection prevention practices among EBMT hematopoietic cell transplant centers: the EBMT Infectious Disease Working Party survey.

Yeshurun M, Rozovski U, Shargian L, Pasvolsky O, van der Werf S, Tridello G, Knelange N, Mikulska M, Styczynski J, Averbuch D, de la Camara R. Yeshurun M, et al. Bone Marrow Transplant. 2023 Apr;58(4):414-423. doi: 10.1038/s41409-023-01916-6. Epub 2023 Jan 18. Bone Marrow Transplant. 2023. PMID: 36653669

5

Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.

Shimoni A, Kröger N, Zander AR, Rowe JM, Hardan I, Avigdor A, Yeshurun M, Ben-Bassat I, Nagler A. Shimoni A, et al. Among authors: yeshurun m. Leukemia. 2003 Feb;17(2):290-7. doi: 10.1038/sj.leu.2402808. Leukemia. 2003. PMID: 12592325 Clinical Trial.

6

A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant.

Laporte JP, Yeshurun M, Fouillard L, Labopin M, Cailliot C, Lesage S, Isnard F, Najman A, Gorin NC. Laporte JP, et al. Among authors: yeshurun m. Leukemia. 2004 Oct;18(10):1717-21. doi: 10.1038/sj.leu.2403427. Leukemia. 2004. PMID: 15295607

7

Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning.

Shimoni A, Kröger N, Zabelina T, Ayuk F, Hardan I, Yeshurun M, Shem-Tov N, Avigdor A, Ben-Bassat I, Zander AR, Nagler A. Shimoni A, et al. Among authors: yeshurun m. Leukemia. 2005 Jan;19(1):7-12. doi: 10.1038/sj.leu.2403591. Leukemia. 2005. PMID: 15526016

8

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity.

Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A. Shimoni A, et al. Among authors: yeshurun m. Leukemia. 2006 Feb;20(2):322-8. doi: 10.1038/sj.leu.2404037. Leukemia. 2006. PMID: 16307018 Clinical Trial.

9

Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Yeshurun M, Labopin M, Blaise D, Cornelissen JJ, Sengeloev H, Vindelov L, Kuball J, Chevallier P, Craddock C, Socie G, Bilger K, Schouten HC, Fegueux N, Goker H, Maertens J, Bunjes D, Arnold R, Nagler A, Mohty M. Yeshurun M, et al. Cancer. 2014 Mar 15;120(6):855-63. doi: 10.1002/cncr.28498. Epub 2013 Dec 10. Cancer. 2014. PMID: 24338939 Free article.

10

Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicities-Substituting the 3rd dose of methotrexate to mycophenolate mofetil.

Ram R, Herscovici C, Dahan D, Israeli M, Dreyer J, Peck A, Shpilberg O, Yeshurun M. Ram R, et al. Among authors: yeshurun m. Leuk Res. 2014 Aug;38(8):913-7. doi: 10.1016/j.leukres.2014.05.020. Epub 2014 Jun 4. Leuk Res. 2014. PMID: 24939215

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

108 results

Search Page

Filters